Graphene hydrogel and method for using the same
Provided herein is a hydrogel composition comprising a graphene, a chitosan, and a polyethylene (glycol) diacrylate (PEGDA) (PCG hydrogel). In some embodiments, the hydrogel further comprises a N-isopropylacrylamide (NIPAM) (TPCG hydrogel). Also provided is a method for differentiating a mesenchymal stem cell comprising contacting the cell with the PCG hydrogel. Further provided herein is a method for delivering a pharmaceutical composition to a cell comprising administering to the cell a TPCG hydrogel and the pharmaceutical composition.
1. A hydrogel composition comprising:
at least two acrylated chitosan-graphene monomers, where each chitosan-graphene monomer comprises:
carboxylic acid functionalized graphene, where the chitosan component of the chitosan graphene-monomer is covalently bonded to the carboxylic acid functionalized graphene component of the chitosan-graphene monomer;
and polyethylene (glycol) diacrylate (PEGDA), where the PEGDA covalently crosslinks the at least two acrylated chitosan-graphene monomers.
2. The hydrogel composition of claim 1 , wherein the non-acrylated chitosan has a molecular weight of 10 kDa.
3. The hydrogel composition of claim 1 , further comprising mesenchymal stem cells.
4. The hydrogel composition of claim 1 , wherein the final weight percent of the functionalized graphene in the hydrogel is less than 0.1 percent.
5. The hydrogel composition of claim 1 , wherein the final weight percent of the functionalized graphene in the hydrogel is 0.08 percent.
6. The hydrogel composition of claim 1 , wherein the PEGDA is between 250 kDa to 6000 kDa.
7. The hydrogel composition of claim 1 , further comprising N-Isopropylacrylamide (NIPAM), where the NIPAM is crosslinked at least one of the at least two acrylated chitosan-graphene monomers.
8. The hydrogel composition of claim 7 , further comprising a pharmaceutical compound contained within the hydrogel.
9. The hydrogel composition of claim 8 , wherein the pharmaceutical compound is doxorubicin.
10. The hydrogel composition of claim 8 , wherein loading weight percent of the pharmaceutical compound in the hydrogel is between 27 wt % and 48 wt %.
11. The hydrogel composition of claim 7 , wherein the hydrogel reversibly decreases in size at a temperature between 36° C. and 42° C.
12. The hydrogel composition of claim 7 , wherein the hydrogel composition further comprises a pharmaceutical compound contained within the hydrogel and wherein the pharmaceutical composition is released from the when the hydrogel reversibly decreases in size at a temperature between 36° C. and 42° C.
13. A temperature responsive hydrogel composition comprising:
at least two acrylated chitosan-graphene monomers, where each chitosan-graphene monomer comprises:
carboxylic acid functionalized graphene, where the chitosan component of the chitosan graphene-monomer is covalently bonded to the carboxylic acid functionalized graphene component of the chitosan-graphene monomer;
polyethylene (glycol) diacrylate (PEGDA), where the PEGDA covalently crosslinks the at least two acrylated chitosan-graphene monomers; and
N-Isopropylacrylamide (NIPAM), where the NIPAM crosslinks at least one of the acrylated chitosan graphene monomers.
14. The temperature responsive hydrogel of claim 13 , wherein the hydrogel is responsive to near infrared light.
15. The temperature responsive hydrogel of claim 13 , wherein the hydrogel reversibly decreases in size at a temperature between 36° C. and 42° C.
16. The temperature responsive hydrogel of claim 13 , further comprising a pharmaceutical compound contained within the hydrogel.
17. The temperature responsive hydrogel of claim 13 , wherein the final weight percent of the functionalized graphene in the hydrogel is less than 0.1 percent.
18. The temperature responsive hydrogel of claim 13 , wherein the hydrogel reversibly decreases in size at a temperature of 42° C.
19. The temperature responsive hydrogel of claim 13 , further comprising a pharmaceutical compound contained within the hydrogel.